Literature DB >> 31425611

Financial conflicts of interest in systematic reviews: associations with results, conclusions, and methodological quality.

Camilla Hansen1, Andreas Lundh, Kristine Rasmussen, Asbjørn Hróbjartsson.   

Abstract

BACKGROUND: Financial conflicts of interest in systematic reviews (e.g. funding by drug or device companies or authors' collaboration with such companies) may impact on how the reviews are conducted and reported.
OBJECTIVES: To investigate the degree to which financial conflicts of interest related to drug and device companies are associated with results, conclusions, and methodological quality of systematic reviews. SEARCH
METHODS: We searched PubMed, Embase, and the Cochrane Methodology Register for studies published up to November 2016. We also read reference lists of included studies, searched grey literature sources, and Web of Science for studies citing the included studies. SELECTION CRITERIA: Eligible studies were studies that compared systematic reviews with and without financial conflicts of interest in order to investigate differences in results (estimated treatment effect and frequency of statistically favourable results), frequency of favourable conclusions, or measures of methodological quality of the review (e.g. as evaluated on the Oxman and Guyatt index). DATA COLLECTION AND ANALYSIS: Two review authors independently determined the eligibility of studies, extracted data, and assessed risk of bias. We synthesised the results of each study relevant to each of our outcomes. For meta-analyses, we used Mantel-Haenszel random-effects models to estimate risk ratios (RR) with 95% confidence intervals (CIs), with RR > 1 indicating that systematic reviews with financial conflicts of interest more frequently had statistically favourable results or favourable conclusions, and had lower methodological quality. When a quantitative synthesis was considered not meaningful, results from individual studies were summarised qualitatively. MAIN
RESULTS: Ten studies with a total of 995 systematic reviews of drug studies and 15 systematic reviews of device studies were included. We assessed two studies as low risk of bias and eight as high risk, primarily because of risk of confounding. The estimated treatment effect was not statistically significantly different for systematic reviews with and without financial conflicts of interest (Z-score: 0.46, P value: 0.64; based on one study of 14 systematic reviews which had a matched design, comparing otherwise similar systematic reviews). We found no statistically significant difference in frequency of statistically favourable results for systematic reviews with and without financial conflicts of interest (RR: 0.84, 95% CI: 0.62 to 1.14; based on one study of 124 systematic reviews). An analysis adjusting for confounding due to methodological quality (i.e. score on the Oxman and Guyatt index) provided a similar result. Systematic reviews with financial conflicts of interest more often had favourable conclusions compared with systematic reviews without (RR: 1.98, 95% CI: 1.26 to 3.11; based on seven studies of 411 systematic reviews). Similar results were found in two studies with a matched design, which therefore had a reduced risk of confounding. Systematic reviews with financial conflicts of interest tended to have lower methodological quality compared with systematic reviews without financial conflicts of interest (RR for 11 dimensions of methodological quality spanned from 1.00 to 1.83). Similar results were found in analyses based on two studies with matched designs. AUTHORS'
CONCLUSIONS: Systematic reviews with financial conflicts of interest more often have favourable conclusions and tend to have lower methodological quality than systematic reviews without financial conflicts of interest. However, it is uncertain whether financial conflicts of interest are associated with the results of systematic reviews. We suggest that patients, clinicians, developers of clinical guidelines, and planners of further research could primarily use systematic reviews without financial conflicts of interest. If only systematic reviews with financial conflicts of interest are available, we suggest that users read the review conclusions with skepticism, critically appraise the methods applied, and interpret the review results with caution.

Entities:  

Mesh:

Year:  2019        PMID: 31425611      PMCID: PMC7040976          DOI: 10.1002/14651858.MR000047.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  39 in total

Review 1.  What do we really know about conflicts of interest in biomedical research?

Authors:  Teddy D Warner; John P Gluck
Journal:  Psychopharmacology (Berl)       Date:  2003-11-18       Impact factor: 4.530

2.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.

Authors:  Gordon Guyatt; Andrew D Oxman; Elie A Akl; Regina Kunz; Gunn Vist; Jan Brozek; Susan Norris; Yngve Falck-Ytter; Paul Glasziou; Hans DeBeer; Roman Jaeschke; David Rind; Joerg Meerpohl; Philipp Dahm; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2010-12-31       Impact factor: 6.437

Review 3.  Meta-analyses with industry involvement are massively published and report no caveats for antidepressants.

Authors:  Shanil Ebrahim; Sheena Bance; Abha Athale; Cindy Malachowski; John P A Ioannidis
Journal:  J Clin Epidemiol       Date:  2015-09-21       Impact factor: 6.437

4.  Epidemiology and reporting of randomised trials published in PubMed journals.

Authors:  An-Wen Chan; Douglas G Altman
Journal:  Lancet       Date:  2005 Mar 26-Apr 1       Impact factor: 79.321

Review 5.  Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review.

Authors:  Anders W Jørgensen; Jørgen Hilden; Peter C Gøtzsche
Journal:  BMJ       Date:  2006-10-06

6.  A new classification of spin in systematic reviews and meta-analyses was developed and ranked according to the severity.

Authors:  Amélie Yavchitz; Philippe Ravaud; Douglas G Altman; David Moher; Asbjørn Hrobjartsson; Toby Lasserson; Isabelle Boutron
Journal:  J Clin Epidemiol       Date:  2016-02-02       Impact factor: 6.437

Review 7.  Industry sponsorship and research outcome.

Authors:  Andreas Lundh; Joel Lexchin; Barbara Mintzes; Jeppe B Schroll; Lisa Bero
Journal:  Cochrane Database Syst Rev       Date:  2017-02-16

8.  Pharmaceutical sponsorship bias influences thrombolytic literature in acute ischemic stroke.

Authors:  Ryan Patrick Radecki
Journal:  West J Emerg Med       Date:  2011-11

9.  Relationship between funding source and conclusion among nutrition-related scientific articles.

Authors:  Lenard I Lesser; Cara B Ebbeling; Merrill Goozner; David Wypij; David S Ludwig
Journal:  PLoS Med       Date:  2007-01       Impact factor: 11.069

Review 10.  An assessment of the methodological quality of published network meta-analyses: a systematic review.

Authors:  James D Chambers; Huseyin Naci; Olivier J Wouters; Junhee Pyo; Shalak Gunjal; Ian R Kennedy; Mark G Hoey; Aaron Winn; Peter J Neumann
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

View more
  12 in total

1.  Are conflict of interest declarations appropriate to allow sufficient consideration of potential bias in presentations?

Authors:  William Crawford; C Fielder Camm; Ishika Prachee; Jack Olivarius-McAllister; Matthew R Ginks; Edward D Nicol
Journal:  Future Healthc J       Date:  2020-10

2.  Addressing Conflicts of Interest and Conflicts of Commitment in Public Advocacy and Policy Making on CRISPR/Cas-Based Human Genome Editing.

Authors:  Alexander Christian
Journal:  Front Res Metr Anal       Date:  2022-04-27

Review 3.  Financial conflicts of interest in systematic reviews: associations with results, conclusions, and methodological quality.

Authors:  Camilla Hansen; Andreas Lundh; Kristine Rasmussen; Asbjørn Hróbjartsson
Journal:  Cochrane Database Syst Rev       Date:  2019-08-05

4.  Conflicts of interest in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: associations with recommendations.

Authors:  Camilla Hansen Nejstgaard; Lisa Bero; Asbjørn Hróbjartsson; Anders W Jørgensen; Karsten Juhl Jørgensen; Mary Le; Andreas Lundh
Journal:  Cochrane Database Syst Rev       Date:  2020-12-08

5.  Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review.

Authors:  Camilla H Nejstgaard; Lisa Bero; Asbjørn Hróbjartsson; Anders W Jørgensen; Karsten J Jørgensen; Mary Le; Andreas Lundh
Journal:  BMJ       Date:  2020-12-09

6.  Effectiveness of Written Dietary Advice for Improving Blood Lipids in Primary Care Adults-A Pragmatic Randomized Controlled Trial (MYDICLIN).

Authors:  Andreas Rydell; Mikael Hellsten; Martin Lindow; David Iggman
Journal:  Nutrients       Date:  2022-02-28       Impact factor: 5.717

7.  Impact of industry sponsorship on the quality of systematic reviews of vaccines: a cross-sectional analysis of studies published from 2016 to 2019.

Authors:  Dawid Pieper; Irma Hellbrecht; Linlu Zhao; Clemens Baur; Georgia Pick; Sarah Schneider; Thomas Harder; Kelsey Young; Andrea C Tricco; Ella Westhaver; Matthew Tunis
Journal:  Syst Rev       Date:  2022-08-22

Review 8.  A tutorial on methodological studies: the what, when, how and why.

Authors:  Lawrence Mbuagbaw; Daeria O Lawson; Livia Puljak; David B Allison; Lehana Thabane
Journal:  BMC Med Res Methodol       Date:  2020-09-07       Impact factor: 4.615

9.  Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration.

Authors:  Jérémie F Cohen; Jonathan J Deeks; Lotty Hooft; Jean-Paul Salameh; Daniël A Korevaar; Constantine Gatsonis; Sally Hopewell; Harriet A Hunt; Chris J Hyde; Mariska M Leeflang; Petra Macaskill; Trevor A McGrath; David Moher; Johannes B Reitsma; Anne W S Rutjes; Yemisi Takwoingi; Marcello Tonelli; Penny Whiting; Brian H Willis; Brett Thombs; Patrick M Bossuyt; Matthew D F McInnes
Journal:  BMJ       Date:  2021-03-15

10.  Alcohol, cardiovascular disease and industry funding: A co-authorship network analysis of systematic reviews.

Authors:  Su Golder; Jim McCambridge
Journal:  Soc Sci Med       Date:  2021-10-01       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.